Display options
Cite
Carter ME, Koch A, Lauer UM, et al. Clinical Trials of Oncolytic Viruses in Breast Cancer. Front Oncol. 2021;11:803050doi: 10.3389/fonc.2021.803050.
Carter, M. E., Koch, A., Lauer, U. M., & Hartkopf, A. D. (2021). Clinical Trials of Oncolytic Viruses in Breast Cancer. Frontiers in oncology, 11803050. https://doi.org/10.3389/fonc.2021.803050
Carter, Mary E, et al. "Clinical Trials of Oncolytic Viruses in Breast Cancer." Frontiers in oncology vol. 11 (2021): 803050. doi: https://doi.org/10.3389/fonc.2021.803050
Carter ME, Koch A, Lauer UM, Hartkopf AD. Clinical Trials of Oncolytic Viruses in Breast Cancer. Front Oncol. 2021 Dec 23;11:803050. doi: 10.3389/fonc.2021.803050. eCollection 2021. PMID: 35004328; PMCID: PMC8733599.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2021 Dec 23;11:803050. doi: 10.3389/fonc.2021.803050. eCollection 2021.

Clinical Trials of Oncolytic Viruses in Breast Cancer.

Frontiers in oncology

Mary E Carter, André Koch, Ulrich M Lauer, Andreas D Hartkopf

Affiliations

  1. Department of Obstetrics and Gynaecology, University of Tuebingen, Tuebingen, Germany.
  2. Department of Internal Medicine VIII, Medical Oncology & Pneumology, University of Tuebingen, Tuebingen, Germany.

PMID: 35004328 PMCID: PMC8733599 DOI: 10.3389/fonc.2021.803050

Abstract

Breast cancer is the second most common kind of cancer worldwide and oncolytic viruses may offer a new treatment approach. There are three different types of oncolytic viruses used in clinical trials; (i) oncolytic viruses with natural anti-neoplastic properties; (ii) oncolytic viruses designed for tumor-selective replication; (iii) oncolytic viruses modified to activate the immune system. Currently, fourteen different oncolytic viruses have been investigated in eighteen published clinical trials. These trials demonstrate that oncolytic viruses are well tolerated and safe for use in patients and display clinical activity. However, these trials mainly studied a small number of patients with different advanced tumors including some with breast cancer. Future trials should focus on breast cancer and investigate optimal routes of administration, occurrence of neutralizing antibodies, viral gene expression, combinations with other antineoplastic therapies, and identify subtypes that are particularly suitable for oncolytic virotherapy.

Copyright © 2021 Carter, Koch, Lauer and Hartkopf.

Keywords: breast cancer; clinical trials; oncolytic virus; review; virotherapy

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publication Types